anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive cemiplimab IV over 30 minutes every 3 weeks. Cycles repeat every 3 weeks for up to 6 weeks with or without radiation therapy at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity.
The present disclosure provides isolated monoclonal antibodies that specifically bind to CD19 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD19. In certain embodiments, the antibodies are capable of internalizing into CD19-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD19, as well as methods for treating cancers, such as B cell malignancies, for example, non-Hodgkin's lymphoma, chronic lymphocytic leukemias, follicular lymphomas, diffuse large cell lymphomas of B lineage, and multiple myelomas using an anti-CD19 antibody of this disclosure.
A resilient multi-layer container is configured to receive a quantity of hyperpolarized noble fluid such as gas and includes a wall with at least two layers, a first layer with a surface which minimizes contact-induced spin-relaxation and a first or second layer which is substantially impermeable to oxygen. The container is especially suitable for collecting and transporting 3He. The resilient container can be formed of material layers which are concurrently responsive to pressure such as polymers, deuterated polymers, or metallic films. The container can include a capillary stem and/or a port or valve isolation means to inhibit the flow of gas from the main volume of the container during transport.  The resilient container can be configured to directly deliver the hyperpolarized noble gas to a target interface by deflating or collapsing the inflated resilient container. In addition, single layer resilient containers with T1's of above 4 hours for 129Xe and above 6 hours for 3He include materials with selected relaxivity values. In addition, a bag with a port fitting or valve member and one or more of a capillary stem and port isolation means is configured to minimize the depolarizing effect of the container valve or fitting(s). Also disclosed is a method for determining the gas solubility in an unknown polymer or liquid using the measured relaxation time of a hyperpolarized gas.
A method is described to transfer a gene encoding a valuable compound, such as a pharmaceutical, into the secretory cells of the mammary gland to produce a new compound into the milk or to alter the composition of the milk. In this method the packaging cell line producing the viral-derived particles is infused into the mammary gland. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles to trans-infect the maximum number of mammary epithelial cells. After a period of time in the mammary gland, both the particles and the packaging cells will be destroyed by natural mechanisms while the trans-infected mammary epithelial cells continue to express gene(s) encoding the valuable compound or gene(s) to alter the composition of the milk. One or more genes can be trans-infected including DNA sequences that contribute to the efficient production of an active compound or to its stability. The packaging cells and the viral-derived particles used in this method can be those which trans-infect dividing or non-dividing cells and can be used either singly or together. This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk.
A kind of cosmetics and preparation method thereof for the rate that wrinkles the invention discloses reduction skin aging, include the following steps：A. the chinese medicine material chosen is handled first；B. it waits for that raw material is carried out drying and processing again after the completion of step a, avoids bacteria breed；C. after the completion of waiting for step b, grinding device is recycled, it is ensured that consistent in density；D. after the completion of waiting for step c, then prepare vegetable fat, naturally occurring emulsifying agent, Botox, vitamin E, azone；E. after the completion of waiting for step d, in the preparation for carrying out cosmetics, traditional Chinese medicine ingredients are formed by using PORIA ALBA, rhizoma typhonii, tribulus terrestris, the bletilla striata, pearl powder, convenient for increasing the skin-friendly of natural environmental-protective and product, the effect for moistening maintenance is played, by during preparation, coordinate the addition of botulin toxin, vitamin E, coordinate the natural skin of the fleece-flower root, Radix Notoginseng to conserve property, increases skin to the corrugated repellence of anti-aging, can greatly improve the using effect of cosmetics.
Participants will use the personal assistant feature of the smartphone ("Cortana") to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state "Cortana, I need to remember to..." for time--based tasks ("...take my medicine at 7pm") and event--based tasks ("pick-up milk at the grocery store).
The invention discloses a medicine of traditional Chinese medicine moxibustion. The traditional Chinese medicine moxibustion is prepared from the following traditional Chinese medicine materials in parts by weight: 0.5-2 parts of frankincense, 0.5-2 parts of myrrh, 2-5 parts of radices sileris, 2-6 parts of radix angelicae pubescentis, 2-3 parts of radix rehmanniae recen, 12-20 parts of crude astragalus mongholicus, 1-3 parts of burdock, 2-6 parts of peach kernel, 0.5-3 parts of coptis root, 20-25 parts of moxa, 1 part of honey-fried licorice root, 1-5 parts of pine stem, 3-8 parts of caulis spatholobi, 1-2 parts of centipede, 1-2 parts of earthworm, 0.5-2 parts of sandalwood, 0.5-3 parts of borneol and 2-8 parts of asarum. The combustion temperature of the traditional Chinese medicine moxibustion is higher than general moxibustion, the temperature is more stable, and the combustion time is longer. The materials are all natural medicine and have no toxic or side effect. The conductivity between the meridians and collaterals is enhanced and is greatly strengthened for patients with a weak moxibustion feeling. The bulk drugs are low in cost, and the traditional Chinese medicine moxibustion inherits a traditional Chinese medicine therapy lasting for thousands of years, so that the concept of green health is truly reflected.
Spinal cord stimulation (SCS) is a well-established treatment for chronic neuropathic pain. However, over- or underdelivery of the SCS may occur because the spacing between the stimulating electrodes and the spinal cord is not fixed; spacing changes with motion and postural shifts may result in variable delivery of the SCS dose and, in turn, a suboptimal therapy experience for the patient. The evoked compound action potential (ECAP)-a measure of neural activation-may be used as a control signal to adapt SCS parameters in real time to compensate for this variability. In this prospective, multicenter, randomized, single-blind, crossover trial, reduction in overstimulation intensity was used as a perceptual measure to evaluate a novel ECAP-controlled, closed-loop (CL) SCS algorithm relative to traditional open-loop (OL) SCS. The primary outcome used a Likert scale to assess sensation during activities of daily living with CL versus OL SCS. Of the 42 subjects in the intent-to-treat analysis set, 97.6% had a reduction in sensation with CL versus OL SCS. The primary objective was met as the lower confidence limit (87.4%) exceeded the performance goal of 50% (P < .001). A total of 88.1% (37/42) of subjects preferred CL and 11.9% (5/42) preferred OL SCS. SCS dose consistency during CL SCS was demonstrated by the reduced variability in ECAP amplitude with CL SCS (standard deviation: 8.72 µV) relative to OL SCS (standard deviation: 19.95 µV). Together, these results demonstrate that the ECAP-controlled, CL algorithm reduces or eliminates unwanted sensation, and thereby provides a more preferred and consistent SCS experience. PERSPECTIVE: Patients with chronic pain need durable and dependable options for pain relief. SCS is an important therapy option, and new technology advancements could improve long-term therapy use. CL SCS offers a preferred and more consistent therapy experience for patients that could lead to increased therapy utilization and reliable therapy outcomes.
Participants will attend one study session after determination of eligibility. During this session, they will smoke a cannabis cigarette with 12.5% THC prior to driving a simulator. Driving will be assessed prior to smoking cannabis and at 7 time points after smoking cannabis. Eye tracking measures will also be taken while driving after smoking cannabis. Blood will be drawn for determination of levels of the psychoactive substance THC and its metabolites. Saliva tests, urine tests and subjective tests will also be performed at various times points after smoking cannabis.
Prediabetes is a heterogenous metabolic state with various risks for development of type 2 diabetes (T2D). In this study, we used genetic data on 7,227 US Hispanic/Latino participants without diabetes from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and 400,149 non-Hispanic White participants without diabetes from the UK Biobank (UKBB) to calculate five partitioned polygenetic risk scores (pPRSs) representing various pathways related to T2D. Consensus clustering was performed in participants with prediabetes in HCHS/SOL (n = 3,677) and UKBB (n = 16,284) separately based on these pPRSs. Six clusters of individuals with prediabetes with distinctive patterns of pPRSs and corresponding metabolic traits were identified in the HCHS/SOL, five of which were confirmed in the UKBB. Although baseline glycemic traits were similar across clusters, individuals in cluster 5 and cluster 6 showed an elevated risk of T2D during follow-up compared with cluster 1 (risk ratios [RRs] 1.29 [95% CI 1.08, 1.53] and 1.34 [1.13, 1.60], respectively). Inverse associations between a healthy lifestyle score and risk of T2D were observed across different clusters, with a suggestively stronger association observed in cluster 5 compared with cluster 1. Among individuals with a healthy lifestyle, those in cluster 5 had a similar risk of T2D compared with those in cluster 1 (RR 1.03 [0.91, 1.18]). This study identified genetic subtypes of prediabetes that differed in risk of progression to T2D and in benefits from a healthy lifestyle.
Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
The PPG Global Registry an investigator-initiated, observational, multicenter study of patients with an indication for PCI based on coronary angiography and FFR ≤0.80. After confirmation of intention to treat with PCI, a manual pullback with PPG analysis will be performed. A second level of decision making is then performed concerning PCI, coronary artery bypass grafting (CABG) or medical therapy (OMT). Patients will undergo PCI at operator discretion and post-PCI FFR will be measured. Clinical follow-up will be performed at 1, 2 and 3 years.
Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
BACKGROUND: Left atrial appendage closure (LAAC) is a treatment modality for stroke prevention in patients with atrial fibrillation (AF). One of the potential complications of LAAC is a peri-device leak (PDL), which could potentially increase the risk of thromboembolism formation.
METHODS: This systematic review was done according to PRISMA guidelines. Using four databases, all primary studies through April 2022 that met selection criteria were included. Outcomes of interest were studies reporting on PDL characteristics, risk factors and management.
RESULTS: A total of 116 studies met selection criteria (97 original studies and 19 case reports/series). In the original studies (n = 30,133 patients), the weighted mean age was 72.0 ± 7.4 years (57% females) with a HAS-BLED and CHA2DS2-VASc weighted means of 2.8 ± 1.1 and 3.8 ± 1.3, respectively. The most common definition of PDL was based on size; 5 mm: major, 3-5 mm: moderate, < 1 mm minor, or trivial. Follow up time for PDL detection was 7.15 ± 9.0 months. 33% had PDL, irrespective of PDL severity/size, and only 0.9% had PDL of greater than 5 mm. The main risk factors for PDL development included lower degree of over-sizing, lower left ventricular ejection fraction, device/LAA shape mismatch, previous radiofrequency ablation, and male sex. The most common methods to screen for PDL included transesophageal echocardiogram and cardiac CT. PDL Management approaches include Amplatzer Patent Foramen Ovale occluder, Hookless ACP, Amplatzer vascular plug II, embolic coils, and detachable vascular coils; removal or replacement of the device; and left atriotomy.
CONCLUSION: Following LAAC, the emergence of a PDL is a significant complication to be aware of. Current evidence suggests possible risk factors that are worth assessing in-depth. Additional research is required to assess suitable candidates, timing, and strategies to managing patients with PDL.
This is an open-label (all people know the identity of the intervention), multicenter (study conducted in multiple sites), non-randomized (patients are not assigned by chance to treatment groups), Phase 2b study. Up to 75 patients with MCD will be eligible for the study, the majority of whom will be on active therapy with siltuximab at the time of enrollment. Patients will be either siltuximab-naive or have not progressed on siltuximab in the opinion of the investigator. Duration of disease control and survival will be assessed. Data collection for patients who discontinue treatment will be limited to survival, occurrence of malignancies, and subsequent therapies for MCD, which will be assessed twice per year until the patient has been lost to follow up or has withdrawn consent for the study, whichever occurs first. An interim analysis will be conducted (no later than 2 years after the start of enrollment) to further evaluate the benefit and safety of long-term treatment with siltuximab in patients with MCD. A data will occur at 6 years after the start of enrollment and for those patients remaining on treatment after the data cutoff, data collection will be limited to pregnancies and serious adverse events (SAEs), including information on study agent administration and concomitant medications associated with an SAE. Safety evaluations for adverse events, clinical laboratory tests, vital signs, and physical examination will be performed throughout the study. The end of study is the date of the last assessment for the last patient.
PURPOSE:To provide the subject protecting agent containing a polypeptide having a human ADF activity as an active ingredient and useful for protecting organs from damages caused by active oxygen on organ transplantation or ischemic reperfusion diseases. CONSTITUTION:The objective protecting agent contains a polypeptide having a human ADF activity (preferably a polypeptide comprising 104 amino acids started from the N-terminal valine represented by the sequence number 1 in the sequence table, and a peptide having a structure to whose end a methionine is addition-reacted) as an active ingredient, and further, if necessary, an excipient and a stabilizer. The polypeptide is obtained e.g. by culturing a man- originated cell strain (e.g. ATL-2 cell) and subsequently purifying the polypeptide from the cultured solution, etc., by a method such as a salting-out method, a gel chromatography, etc. The content of the human ADF is preferably 10-80 pts.wt. per 100 pts.wt. of the protecting agent, and the protecting agent is administered at a dose of 10mug to 10mg/kg once to several times a day.
Epithelial Ovarian Cancer (EOC) poses a significant challenge in the field of gynecological oncology regarding precise early screening. In response to this critical scientific issue, the research team has designed and developed a high-sensitivity, high-specificity enrichment SERS chip, exploring its applications in the screening and diagnosis of ovarian cancer. The development of the SERS chip and its functional implementation has been done.Clinical research trials are conducted for ovarian cancer screening and diagnosis, analyzing the physicochemical properties of key biomolecules in the blood of ovarian cancer patients. The study reveals the interaction patterns between SERS active particles and biomolecules, establishing a competitive adsorption model between multiple biomolecules and active particles. Raman spectra of individual components are collected to create a characteristic Raman information database for key biomolecules.

The analysis of Raman spectra from ovarian cancer patients and healthy individuals delves into the characteristic signals, constructing a statistical classification model for patient and normal Raman signals. Different tissue types and grades of ovarian cancer patients' Raman spectra signals are analyzed, establishing high-throughput classification methods for various ovarian cancers. By combining clinical gold-standard detection techniques, the sources of characteristic signals are determined, providing a theoretical foundation and technical support for conducting ovarian cancer research and establishing treatment plans in clinical settings.
The invention provides a traditional Chinese medicine for treating blood deficiency and wind dryness type chronic urticaria. The traditional Chinese medicine is prepared from cornu bubali, rhizomes of rehmannia, puncturevine caltrop fruit, caulis spatholobi, zaocys dhumnade, periostracum cicada, radix salvia miltiorrhiza, cortex lycii radicis, cortex dictamni, cortex mori, caulis polygoni multiflori, radix codonopsis, rhizoma atractylodis macrocephalae and prepared licorice roots. The dosage of the traditional Chinese medicine can be increased and decreased according to the differences of the symptoms such as urticaria red and swollen, itching discomfort, vexation and irritability, long disease course and the like. According to the traditional Chinese medicine, all the Chinese herbs are jointly used to achieve the effects of nourishing blood to expel wind, moistening dryness to relieve itching, enhancing the immunity of the organism and treating both symptoms and root causes. Meanwhile, the traditional Chinese medicine is convenient to prepare and apply and free of toxic and side effects. Through application verification, the traditional Chinese medicine is significant in treatment effect, reliable in effect and mild in medicine property, the effective rate is 86%, and the cure rate reaches 78%.
INTRODUCTION: Despite evidence supporting the benefits of marriage on cardiovascular health, the impact of marital/partner status on the long-term readmission of young acute myocardial infarction (AMI) survivors is less clear. We examined the association between marital/partner status and 1-year all-cause readmission and explored sex differences among young AMI survivors.
METHODS: Data were from the VIRGO study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients), which enrolled young adults aged 18-55 years with AMI (2008-2012). The primary end point was all-cause readmission within 1 year of hospital discharge, obtained from medical records and patient interviews and adjudicated by a physician panel. We performed Cox proportional hazards models with sequential adjustment for demographic, socioeconomic, clinical, and psychosocial factors. Sex-marital/partner status interaction was also tested.
RESULTS: Of the 2,979 adults with AMI (2002 women [67.2%]; mean age 48 [interquartile range, 44-52] years), unpartnered individuals were more likely to experience all-cause readmissions compared with married/partnered individuals within the first year after hospital discharge (34.6% versus 27.2%, hazard ratio [HR] = 1.31; 95% confidence interval [CI], 1.15-1.49). The association attenuated but remained significant after adjustment for demographic and socioeconomic factors (adjusted HR, 1.16; 95% CI, 1.01-1.34), and it was not significant after further adjusting for clinical factors and psychosocial factors (adjusted HR, 1.10; 95%CI, 0.94-1.28). A sex-marital/partner status interaction was not significant (p = 0.69). Sensitivity analysis using data with multiple imputation and restricting outcomes to cardiac readmission yielded comparable results.
CONCLUSIONS: In a cohort of young adults aged 18-55 years, unpartnered status was associated with 1.3-fold increased risk of all-cause readmission within 1 year of AMI discharge. Further adjustment for demographic, socioeconomic, clinical, and psychosocial factors attenuated the association, suggesting that these factors may explain disparities in readmission between married/partnered versus unpartnered young adults. Whereas young women experienced more readmission compared to similar-aged men, the association between marital/partner status and 1-year readmission did not vary by sex.
Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.